Evidence map›Paper›PMID 41158392›Full record

ArticleJournal of thoracic disease2025

PSMD11 facilitates immune escape by recruiting USP14 to modulate the deubiquitinating degradation of PD-L1 in non-small cell lung cancer.

Yong Xi, Pengpeng Yang, Jing Zeng, Yundong Zhou, Akshay J Patel, Weiyu Shen, Xiaoming Liu, Retnagowri Rajandram, Sivakumar Krishnasamy

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yong Xi *Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Pengpeng Yang *Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Jing ZengDepartment of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.
Yundong ZhouDepartment of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.
Akshay J PatelInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Weiyu ShenDepartment of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.
Xiaoming LiuDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Retnagowri RajandramDepartment of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Sivakumar KrishnasamyDivision of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The PSMD11 has been shown to be associated with the malignant progression and clinical outcomes of various carcinomas. However, the molecular mechanism of PSMD11 in non-small cell lung cancer (NSCLC) remains unknown. In this study, we investigated the molecular mechanism of PSMD11 effect on the immune escape in NSCLC. Methods: Co-culture models of NSCLC cells and T cells were constructed. Colony formation assays and flow cytometry were used to detect the proliferation and apoptosis of NSCLC cells in the co-culture system after the knock down of PSMD11. Western blotting was used to detect the expression of programmed death-ligand 1 (PD-L1) after the knock down of PSMD11. Co-immunoprecipitation (co-IP) assays were used to observe the interaction between PD-L1 and PSMD11 and USP14 in the A549 and H1299 cells. The in vivo effects of PSMD11 were analyzed using a xenograft tumor model. Results: In the NSCLC cell/T cell co-culture models, the knockdown of PSMD11 significantly upregulated T cell-mediated apoptosis and enhanced the killing effect of T cells in the A549 and H1299 cells, and also significantly upregulated the expression of killer T cell markers Granzyme and perforin in the T cells. We also found that the knockdown of PSMD11 inhibited the expression of PD-L1. The mass spectrometry (MS) and co-IP results showed that PSMD11 interacted with PD-L1 and the deubiquitinating enzyme USP14. Overexpression of USP14 leads to an increase in the protein level of PD-L1, while knocking down PSMD11 can reverse this elevated state. The overexpression of PD-L1 and USP14 in the NSCLC cells reversed the effects of PSM11 on immune escape. Conclusions: This study showed that PSMD11 recruits USP14 to modulate the deubiquitinating degradation of PD-L1 to promote immune escape in NSCLC.

Indexed as

immune escapenon-small cell lung cancer (NSCLC)programmed death-ligand 1 (PD-L1)PSMD11USP14

Identifiers

PMID41158392
PMCPMC12557654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.